Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
$86.40
$0.91(2.52%)
At close: 4:00 PM EST
$86.40
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$36.36 - $120.74
Previous CloseN/A
Volume639.07K
Average Volume (3M)1.93M
Market Cap
$10.78B
Enterprise Value$12.44B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$1.68B
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Apr 30, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding131,170,440
10 Day Avg. Volume2,252,408
30 Day Avg. Volume1,928,011
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue12.66
Enterprise Value/Gross Profit19.64
Enterprise Value/Ebitda-33.26
Forecast
1Y Price Target
$131.41Price Target Upside52.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.95
Revenue Forecast (FY)$1.27B
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Screening GrowthRapid adoption of the Shield blood-based colorectal screening test, supported by an expanding salesforce and high patient adherence, should drive growing screening volumes and expand the addressable market.
Oncology Product Momentum And Path To ProfitabilityStronger-than-expected oncology testing revenue alongside uptake of therapy selection and MRD products and declining cash burn point toward improving margins and movement toward cash flow breakeven excluding screening investment.
Regulatory And ReimbursementFDA approval of the G360 Liquid test combined with a special Medicare reimbursement designation may increase Medicare payment rates and broaden coverage, supporting higher testing volumes and revenue.
Bears Say
Clinical Trial And Diagnostic Performance RiskLower-than-anticipated sensitivity in a pivotal screening trial and a missed endpoint in a separate multi-cancer study raise concerns about clinical validity and may slow adoption of multi-cancer detection tests.
Financial Sustainability And Cash BurnContinued operating losses and persistent negative profitability measures indicate ongoing cash burn and increase the risk that additional funding or operational changes will be required to sustain growth.
Patent Litigation ExposureA jury finding of willful patent infringement and unresolved patent challenges leave the company exposed to potential enhanced damages and ongoing royalty obligations until all legal issues are fully resolved.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $36.36 and its highest was $120.74 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $10.78B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 19, 2026. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.767 by -$0.233.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.81.
How many shares outstanding does Guardant Health have?
Guardant Health has 131,170,440 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$1 in its last earnings report, missing expectations of -$0.767. Following the earnings report the stock price went down -3.083%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.41 (52.09% Upside)
$131.41 (52.09% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 227.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.31%
12-Months-Change
Fundamentals
Return on Equity
164.85%
Trailing 12-Months
Asset Growth
35.54%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive growth and execution story: strong revenue and volume growth across oncology and screening, improved gross margins and reduced per-test costs (notably for Reveal), meaningful commercial traction for Shield (high adherence, ADLT reimbursement, EMR integrations, Quest/PathGroup partnerships), and improved profitability trends with a solid cash runway. At the same time, significant near-term investments—primarily in Shield—continue to drive company-wide cash burn and operating expenses, and several important upside catalysts (FDA approvals, additional reimbursements, co-promotion benefits) remain uncertain and are not included in the base guidance. Overall the company is growing rapidly with improving margins and clearer path to profitability, but execution and reimbursement risks and continued screening-related cash burn temper the near-term financial picture.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$131.41
▲(52.09% Upside)
Technical Analysis
Ownership Overview
3.61% Insiders
31.14% Mutual Funds
0.04% Other Institutional Investors
49.72% Public Companies and Individual Investors